Does PRP Work for Everyone? The Honest Candidate-vs-Non-Candidate Framework That Most Clinics Won’t Show You in 2026

Introduction: The Question Every Honest PRP Provider Should Answer

Platelet-rich plasma (PRP) has been marketed as a near-miraculous breakthrough therapy, promising to heal joints, regrow hair, and help patients sidestep surgery. Yet the clinical reality is far more nuanced. Outcomes vary dramatically from one patient to the next, and from one condition to another. Anyone searching for an honest answer to “does PRP work for everyone?” deserves more than a glossy sales pitch.

The honest answer is no. PRP does not work for everyone. A review of 12 studies published in PMC/NIH found an aggregate musculoskeletal success rate of approximately 54.8%, defined as more than 50% symptom relief after therapy. That is a meaningful result for many people, but it falls far short of the universal success some clinics imply.

This article offers something most clinic content does not: a transparent, evidence-based framework that maps out both who PRP is likely to help and who it is likely to fail. At Unicorn Bioscience, a regenerative medicine practice operating across Texas, Florida, and New York, the philosophy is straightforward. A provider honest enough to tell a patient when PRP may not be the right choice is, itself, a differentiator in a field prone to overselling. One transparency signal worth noting throughout: PRP devices are FDA-cleared, but the injections themselves are used off-label.

What PRP Actually Is and What It Is Not

PRP is a concentration of a patient’s own platelets. A provider draws blood, processes it in a centrifuge to separate and concentrate the platelets, then injects that concentrate into a target tissue such as a knee joint, a tendon, or the scalp.

The biological rationale is straightforward. Platelets release growth factors, including PDGF-BB, IGF-1, and TGF-beta, that stimulate tissue repair, reduce inflammation, and promote cellular regeneration. In effect, PRP amplifies the body’s own healing signals.

It is equally important to understand what PRP is not. It is not a drug. It is not stem cell therapy. And it is not a guaranteed cure. It is a biologic adjunct, not a magic bullet.

The regulatory reality deserves clarity. The FDA clears the devices used to make PRP, such as centrifuges and preparation kits, through the 510(k) process. The injections themselves are used off-label across orthopedics, dermatology, and hair restoration. This is not illegal, and it is common practice in medicine, but patients deserve to know it. Providers who disclose off-label status are demonstrating transparency. Those who imply the FDA has “approved” the injections are not being fully accurate.

There is also a foundational challenge: a lack of standardized protocols. As documented in a May 2026 KevinMD analysis, there is still no universal consensus on preparation methods, platelet concentration targets, injection frequency, or post-treatment care.

The Honest Success Rate Picture: What the Data Actually Shows

The aggregate figure of 54.8% across musculoskeletal conditions is the right place to start. This is not a failure rate. More than half of appropriately treated patients experienced substantial symptom relief. But it falls far short of the near-universal success rates implied by some marketing materials.

The most important insight is that success rates are highly condition-specific and patient-specific. The diagnosis being treated is one of the strongest predictors of whether PRP will work.

Condition-by-Condition Success Rate Breakdown

• Knee osteoarthritis (mild to moderate): Among the strongest evidence bases for PRP. A 2025 meta-analysis examining knee osteoarthritis outcomes showed WOMAC scores exceeded the 6.4-point Minimal Clinically Important Difference at every timepoint through 12 months, but only when platelet concentration exceeded 1 million platelets per microliter.
• Plantar fasciitis: Strong outcomes have been reported, with one PMC/NIH study observing efficacy in 93.57% of 140 patients overall. Age was the only significant demographic factor influencing efficacy.
• Hair loss (androgenetic alopecia): A 70 to 80% success rate for patients with early to moderate hair loss, with roughly 84% of studies showing PRP is effective for hair thinning. A 2025 clinical study reported hair density increased by approximately 19.1% from baseline at six months after three monthly sessions.
• Where PRP performs no better than placebo: A series of well-designed trials published in JAMA in 2021 found PRP did not outperform placebo for knee osteoarthritis in certain trial designs, ankle osteoarthritis, and Achilles tendinitis. Both Harvard Health and WebMD report this prominently.
• Emerging applications: A 2023 JAMA study found PRP was 12.5 times more likely to improve COVID-19-related smell loss versus placebo, and a 2025 study found 67% of anosmia patients from head injuries improved after PRP. These results are promising but not yet standard of care.

The Green Light / Red Light Patient Profile Matrix

The following framework is a self-assessment tool patients can use before a consultation. It does not replace clinical evaluation. Its purpose is to help patients walk in informed, ask better questions, set realistic expectations, and recognize red flags worth raising with a provider. It synthesizes biological, lifestyle, and condition-severity factors that most clinic content rarely presents in one place.

Green Light Indicators: Patients Most Likely to Benefit from PRP

• Mild to moderate osteoarthritis (Kellgren-Lawrence Grades 1 to 3): Cartilage and joint space are still present, giving PRP’s growth factors a viable environment to work with.
• Early to moderate androgenetic alopecia: Weakened but viable follicles are still present. PRP strengthens existing follicles; it cannot resurrect dead ones.
• Younger patients: Research confirms younger patients have higher platelet concentrations in both blood and PRP (p=0.003 to 0.004) and higher growth factor levels, correlating with better outcomes.
• Healthy BMI (below 30 kg/m²): Lower mechanical joint stress and a better metabolic environment for regeneration.
• Non-smokers with moderate or no alcohol use: Smoking reduces platelet quality; alcohol diminishes regenerative response.
• Good glycemic control (HbA1c at or below 7%): Better healing capacity.
• Realistic expectations: Patients who view PRP as symptom management and healing support, rather than a guaranteed cure, report higher satisfaction.
• Willingness to engage in multimodal care: PRP combined with physical therapy outperforms PRP alone; PRP combined with microneedling or minoxidil enhances hair outcomes.
• Adequate platelet baseline: Blood that yields PRP above 1 million platelets per microliter.

Red Light Indicators: Patients Who Are Poor Candidates for PRP

• Blood clotting disorders (e.g., hemophilia): An absolute contraindication, as noted by PRPmed.de.
• Anticoagulant medications (warfarin, direct oral anticoagulants, clopidogrel): These impair platelet function and can make PRP both less effective and potentially riskier. Patients should always disclose all medications.
• Thrombocytopenia (low platelet count): The concentrate will not reach therapeutic thresholds regardless of technique.
• Active infections (HIV, Hepatitis C, local infection at the site): Safety concerns and compromised healing present significant risks.
• Pregnancy: Generally contraindicated due to insufficient safety data.
• Active skin conditions at the treatment site (severe eczema, rosacea flare, active acne): Increased infection risk.
• End-stage or severe osteoarthritis (Kellgren-Lawrence Grade 4 / bone-on-bone): The biological substrate PRP requires is largely absent. These patients are often better served by other interventions.
• High BMI (30 kg/m² or above): Research on PRP outcomes found BMI at or above 30 was a significant independent predictor of PRP failure, linked to additional mechanical stress on the joint and diminished treatment effectiveness.
• Active smokers: Consistently associated with higher failure rates.
• Poor glycemic control (HbA1c above 7%): Impairs the healing response.
• Completely bald areas with no viable follicles: PRP cannot regenerate follicles that are entirely gone.
• Unrealistic expectations: A recognized non-medical contraindication. Patients expecting cartilage regeneration or a permanent cure report lower satisfaction even when objective improvement occurs.

The Biological Variables That Predict PRP Outcomes

Why can two patients with the same diagnosis have very different results? The answer lies in a set of underlying factors that separate informed patient selection from one-size-fits-all treatment.

Platelet Concentration: The Quality Threshold That Matters Most

Not all PRP is created equal. The concentration of platelets in the final product varies based on baseline blood counts, the preparation system used, and the centrifugation protocol.

The threshold matters. PRP below 1,000,000 platelets per microliter consistently underperforms in clinical studies. The 2025 Bensa meta-analysis found that knee OA outcomes exceeding the Minimal Clinically Important Difference were achieved only when concentration exceeded this level.

The practical implication is significant: patients should ask what platelet concentration a provider’s system achieves and whether it is measured. A provider who cannot answer may be using a lower-quality preparation system. This is a key reason outcomes vary so dramatically. The same “PRP” label can represent very different biological products.

Age, BMI, and Lifestyle: Modifiable and Non-Modifiable Factors

• Age: Younger patients produce PRP with higher platelet and growth factor levels, as documented in PMC/NIH research. This is non-modifiable, but it informs realistic expectations. Older patients are not excluded; they should simply understand the biological context.
• BMI: A modifiable factor. BMI at or above 30 is linked to diminished effectiveness and additional mechanical joint stress. Weight management may improve candidacy.
• Smoking: Reduces platelet quality and growth factor release. Cessation before and during treatment is advisable.
• Glycemic control: HbA1c above 7% impairs healing. Optimizing this before treatment can improve a patient’s profile.
• Sedentary behavior post-treatment: Appropriate activity and physical therapy after injection support better outcomes.

Disease Severity: Why Timing Matters

PRP is most effective earlier in the disease course. For osteoarthritis, that means Kellgren-Lawrence Grades 1 through 3, where cartilage and joint space remain. Grade 4 (bone-on-bone) is generally a poor indication.

The same principle applies to hair loss: PRP works when follicles are weakened but still viable. Waiting until they are entirely gone closes the treatment window. Patients who are uncertain may benefit from earlier evaluation rather than waiting until candidacy narrows. It also explains why a poor candidate today might become a reasonable one after addressing modifiable factors and reassessing.

Why PRP Outcomes Vary So Much: The Standardization Problem

A major reason PRP results are inconsistent is not patient biology alone. It is the profound lack of standardized protocols across the field.

As of 2026, there is no universal consensus on preparation methods, concentration targets, injection frequency, number of sessions, or post-treatment care. A 2026 Journal of Cosmetic Dermatology review on androgenetic alopecia specifically noted that variability in preparation and application has led to inconsistent outcomes, even when treating the same condition.

This means PRP at one clinic may be a fundamentally different product than PRP at another. Patients should ask: What preparation system do you use? What platelet concentration does it achieve? How many sessions do you recommend and why? Do you use imaging guidance for delivery?

This is where Unicorn Bioscience’s approach stands out. The practice uses precision-guided injection technology with ultrasound and X-ray imaging to ensure accurate delivery to the target tissue, a meaningful differentiator in a field where injection accuracy significantly affects outcomes. The evidence base continues to evolve as well; a 2026 multicenter real-world evidence study is actively recruiting to evaluate PRP for tendinopathies.

When PRP Is Not the Best Option: What Comes Next

If PRP is not the right fit, the conversation should not end there. Patients deserve a clear understanding of alternatives.

• End-stage osteoarthritis: Options such as BMAC (Bone Marrow Aspiration Concentrate), hyaluronic acid viscosupplementation, or a surgical consultation may be more appropriate pathways.
• Hair loss with absent follicles: Surgical hair restoration (FUE/FUT) may be the better intervention, with PRP sometimes used as an adjunct to support graft survival.
• Modifiable red light factors: A structured plan to address smoking, BMI, or glycemic control can convert a poor candidate into a reasonable one.
• Conditions with weak trial evidence (ankle OA, certain Achilles presentations): Alternative evidence-based approaches should be discussed openly.

A provider who acknowledges that PRP may not be the best option is not losing a patient; they are building trust, the foundation of good medicine. Unicorn Bioscience’s multimodal treatment menu, including stem cell therapy, BMAC, exosomes, hyaluronic acid, and peptide therapy, means patients who are not ideal PRP candidates may still have meaningful non-surgical options available to them.

How to Evaluate a PRP Provider: Questions That Separate Credible Practices from Oversellers

These questions are not adversarial. They are the mark of an informed patient, and any credible provider will welcome them.

1. Do you use imaging guidance (ultrasound or X-ray) for injection delivery? Unguided injections may miss the target tissue entirely.
2. What platelet concentration does your system achieve? Look for a benchmark at or above 1 million platelets per microliter.
3. Will you tell me honestly if I am not a good candidate? A provider who screens everyone in is a red flag.
4. What is the FDA regulatory status of PRP injections? The accurate answer: devices are FDA-cleared, and injections are off-label.
5. What does the evidence show for my specific condition? Providers should distinguish strong-evidence conditions (knee OA, plantar fasciitis, androgenetic alopecia) from weaker ones.
6. What is your recommended protocol and why? There should be a clear rationale for session frequency and number.
7. What are my alternatives if PRP does not work? A credible provider has a plan B and is willing to discuss it upfront.

Conclusion: The Honest Answer to “Does PRP Work for Everyone?”

No. PRP does not work for everyone, and any provider who implies otherwise is not giving the full picture.

PRP achieves clinically meaningful improvement in roughly 50 to 70% of appropriately selected musculoskeletal patients and 70 to 80% of hair loss patients with early to moderate disease. Outcomes depend heavily on condition type, disease severity, patient biology, lifestyle factors, and the quality of the preparation and delivery system used.

The Green Light / Red Light matrix is a starting point for self-assessment, not a replacement for clinical evaluation. It gives patients the language and knowledge to have a more informed conversation. The evidence base is active and advancing, with ongoing trials in 2026 refining patient selection criteria and protocols, and the field is moving toward greater standardization that should improve predictability over time.

The most important step a patient can take is finding a provider who is honest about both the promise and the limitations of PRP, and who has the clinical depth to offer meaningful alternatives to surgery when PRP is not the right fit. Unicorn Bioscience is built on exactly that foundation: transparency, precision, and personalized care, including the willingness to say “PRP may not be right for you” when the evidence and an individual’s profile point that way.

Ready to Find Out If PRP Is Right for You? Start with an Honest Conversation.

Unicorn Bioscience offers consultations in person across eight locations in Texas, Florida, and New York, as well as virtually for those outside these areas.

This is an evaluation, not a sales appointment. The goal is to assess whether PRP, or another regenerative therapy, is genuinely appropriate for a patient’s specific condition, biology, and goals. If PRP is not the right fit, the clinical team has the expertise and treatment menu to explore other evidence-based options, including BMAC, exosome therapy, hyaluronic acid, and peptide therapy.

Treatment protocols are developed based on individual factors: inflammation levels, age, injury type, current medications, and personal health goals. A one-size-fits-all template is never the approach.

To schedule a consultation, visit unicornbioscience.com or call (737) 347-0446. Patients who come to Unicorn Bioscience will receive an honest assessment, including an honest answer if PRP is not their best path forward.